Omeros Q2: YARTEMLEA net rev $28.5M (+190% QoQ); adjusted EPS $0.02 vs -$0.24

OMEROS CORP

YARTEMLEA net revenue $28.5M in Q2 2026 (gross $32.2M), up 190% from Q1 gross $11.1M; gross-to-net ~11.5%.
GAAP net income $13.2M ($0.18/sh) vs $56.1M ($0.78) in Q1; non-GAAP adjusted net income $1.8M ($0.02) vs -$17.1M ($0.24).
Cash and short-term investments $132.0M at June 30, 2026; Q2 operating cash flow $4.1M.
In July, repurchased $30.5M principal of 2029 notes for $60.2M, cutting outstanding to $40.3M and conversion shares from ~11.4M to 6.5M.
CHMP negative opinion on narsoplimab MAA for TA-TMA in June; re-examination requested. J-code effective July 1, NTAP effective Oct 1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.